IL10 and Hodgkins lymphoma: This study revealed that the anti-CD20 antibody has no effect on Daudi and Ramos cells but acts synergistically with cisplatin on the two non-Hodgkin's lymphoma 2F7 and 10C9 cells, resulting in the down-regulation of IL-10, another cytokine activating STAT family proteins and involved in cell resistance to treatment.